4.74
+0.06(+1.28%)
Currency In USD
| Previous Close | 4.68 |
| Open | 3.97 |
| Day High | 4.74 |
| Day Low | 3.97 |
| 52-Week High | 6.19 |
| 52-Week Low | 3.36 |
| Volume | 2,861 |
| Average Volume | 4,703 |
| Market Cap | 177.26M |
| PE | -2.37 |
| EPS | -2 |
| Moving Average 50 Days | 3.78 |
| Moving Average 200 Days | 4 |
| Change | 0.06 |
If you invested $1000 in Molecular Partners AG (MOLN) since IPO date, it would be worth $241.22 as of November 09, 2025 at a share price of $4.74. Whereas If you bought $1000 worth of Molecular Partners AG (MOLN) shares 3 years ago, it would be worth $736.02 as of November 09, 2025 at a share price of $4.74.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Molecular Partners presents additional preclinical proof-of-concept data on logic-gated CD3 Switch-DARPin at SITC 2025
GlobeNewswire Inc.
Nov 03, 2025 6:00 AM GMT
Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM I
Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 6:00 AM GMT
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
GlobeNewswire Inc.
Oct 30, 2025 8:00 PM GMT
IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program to be presen